Drug approval challenges in the age of personalized cancer treatment

Personalized Medicine
Richard L Schilsky

Abstract

Cancer treatment is in evolution from nonspecific cytotoxic drugs that damage both tumor and normal cells to more targeted agents and immunotherapy approaches that target unique molecular features of cancer cells or that modulate the tumor immune response to produce greater effectiveness with less toxicity. The development and use of such approaches in biomarker-defined populations enables a more personalized approach to cancer treatment than previously possible and potentially improves the effectiveness, reduces the toxicity and lowers the cost of cancer care although significant barriers remain to realizing the vision of personalized cancer treatment.

References

Jun 21, 2002·The New England Journal of Medicine·Andreas RosenwaldUNKNOWN Lymphoma/Leukemia Molecular Profiling Project
Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
Dec 20, 2002·The New England Journal of Medicine·Marc J van de VijverRené Bernards
Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giuseppe GiacconeDavid H Johnson
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstDavid H Johnson
Dec 14, 2004·The New England Journal of Medicine·Soonmyung PaikNorman Wolmark
Feb 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sae-Won HanNoe Kyeong Kim
Feb 25, 2005·The New England Journal of Medicine·Susumu KobayashiBalázs Halmos
Mar 11, 2005·The New England Journal of Medicine·Monika E HegiRoger Stupp
Aug 18, 2005·Journal of the National Cancer Institute·Lisa M McShaneUNKNOWN Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics
Feb 3, 2006·Cancer Research·Kathryn E O'ReillyNeal Rosen
Sep 8, 2006·The New England Journal of Medicine·Ken A OlaussenUNKNOWN IALT Bio Investigators
Jan 9, 2008·Cancer Investigation·Jeffrey PeppercornLisa A Carey
Jan 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Astrid LièvrePierre Laurent-Puig
Mar 5, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rafael G AmadoDavid D Chang
May 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey A Engelman, Pasi A Jänne
Oct 24, 2008·The New England Journal of Medicine·Christos S KarapetisJohn R Zalcberg
Apr 3, 2009·The New England Journal of Medicine·Eric Van CutsemPhilippe Rougier
May 13, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carolyn D SeibBrent T Shoji
Jul 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sumithra J Mandrekar, Daniel J Sargent
Aug 12, 2009·Journal of the National Cancer Institute·Nicole MittmannUNKNOWN Australasian Gastrointestinal Interest Group
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Oct 27, 2009·Journal of the National Cancer Institute·Sheila E TaubeSteven I Gutman
Sep 8, 2010·The New England Journal of Medicine·Keith T FlahertyPaul B Chapman
Mar 1, 2009·Journal of Oncology Practice·Robert L ComisLinda G Kimmel
Oct 29, 2010·The New England Journal of Medicine·Eunice L KwakA John Iafrate
Feb 2, 2011·Nature Reviews. Drug Discovery·Mark McClellanDavid Kessler
Mar 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nikhil WagleLevi A Garraway
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Jun 7, 2011·The New England Journal of Medicine·Caroline RobertJedd D Wolchok
Jul 12, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yang XieIgnacio I Wistuba

❮ Previous
Next ❯

Citations

Oct 23, 2015·Journal of Comparative Effectiveness Research·Ruth SchwarzerUwe Siebert

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Nature Reviews. Drug Discovery
Richard L Schilsky
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Saiama N WaqarGideon M Blumenthal
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
Markus Lusser
International Journal of Surgical Oncology
Dae Dong Kim, Cathy Eng
© 2022 Meta ULC. All rights reserved